… Erlotinib and gefitinib are similar in efficacy and pharmacokinetics but have some differences
… is approved in second and third line treatment in patients unselected for EGFR mutations. …

… for the treatment of advanced NSCLC in the second- or third-line setting … compared with
standard second-line chemotherapy. In view of this, we believe that erlotinib and gefitinib …

… with advanced non-small cell lung cancer (NSCLC), targeted … Although there is no difference
in statistics, we believe that … for third-line or more-line treatment of advanced lung cancer …

… on efficacy and toxicity between mono-therapy and doublets … survival benefit from gefitinib
and erlotinib. The second-line … comparison of different drugs efficacy in the third-line therapy, …

… Phase III trials suggest that no major efficacy differences exist … was registered for second-
and third-line therapy of … , first-line gefitinib improved PFS compared with chemotherapy. Similar …

… amount of third-line treatment following erlotinib versus … established the efficacy of erlotinib
compared with BSC and … either erlotinib/gefitinib or docetaxel as second-line treatment …

… toxic side-effects with lack of efficacy. Aim of our study was to … ) erlotinib and gefitinib are all
acceptable choices for third-line … The difference in time to progression and overall survival in …

… This article reviews the efficacy and tolerability of gefitinib in this indication and briefly …
to third-line treatment with gefitinib), which may offset the between-group difference in PFS [57]. …

… conducting a phase III trial to directly compare the efficacy and toxicity between gefitinib and
… increases, the need for effective second- or even third-line therapy has been increasing. …

… about enhanced toxicity or decreased efficacy. Secondline … Phase III study comparing
oral topotecan to intravenous … trial of erlotinib in advanced non-small cell lung cancer. J Natl …